By Coloradoan staff

InViragen, a small biotechnology company in Fort Collins, received a
two-year $600,000 grant from the National Institutes of Health to work
with the University of Wisconsin to develop a safe and effective avian
flu vaccine.

The grant will fund construction and testing of novel vaccines
designed to protect against the H5N1 avian flu virus.

"This new project combines Inviragen's expertise in genetic
engineering of vaccines for respiratory diseases with the influenza
expertise at the University of Wisconsin," InViragen CEO Dan
Stinchcomb said in a statement.

Stinchcomb was not available for comment Tuesday.

InViragen also announced it was received financial support from the
Pediatric Dengue Vaccine Initiative to pay for InViragen's dengue
vaccine in preparation for testing in human clinical trials.

About 100 million people living mostly in tropical and subtropical
countries are infected with Dengue fever each year.

In Viragen's dengue vaccine was designed through a collaboration with
the Centers for Disease Control and Prevention in Fort Collins.

For more on this story see Wednesday's Coloradoan.

http://www.coloradoan.com/apps/pbcs.dll/article?AID=/20071127/UPDATES...

Ref:
http://www.inviragen.com/index.php